FDA provides advice for chronic fatigue syndrome drug development
This article was originally published in Scrip
Executive Summary
In designing clinical trials to test experimental therapies to treat chronic fatigue syndrome (CFS), also known as myalgic encephalomyelitis (ME), manufacturers should select efficacy endpoints that include symptoms reported by patients using well-defined and reliable patient-reported outcomes instruments, the FDA said on 10 March in unveiling new draft guidance.